mProX™ Human EPHB2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Christopher
Verified Customer
Timothy
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Validation of EphB2 expression after CRISPR-mediated activation in AGS and HGC27 cell lines.
Western blotting, flow cytometry, and qPCR were used to compare the altered EphB2 expression to the WT control. The EphB2 activator treatment resulted in a significant upregulation of EphB2 expression in both AGS and HGC27 cells, according to the flow cytometric results. The flow cytometry result was validated by the Western blotting.
Ref: Yin, Jie, et al. "EphB2 represents an independent prognostic marker in patients with gastric cancer and promotes tumour cell aggressiveness." Journal of Cancer 11.10 (2020): 2778.
Pubmed: 32226496
DOI: 10.7150/jca.38098
Research Highlights
Based on these findings, EphB2 is a crucial modulator of stress susceptibility and may be a promising target for depression treatment.
Zhang, Ruo-Xi, et al. "EphB2 in the medial prefrontal cortex regulates vulnerability to stress." Neuropsychopharmacology 41.10 (2016): 2541-2556.
Pubmed:
27103064
DOI:
10.1038/npp.2016.58
High EPH/EFN mRNA expression is an independent predictor of poor survival, according to the EPH/EFN cluster analysis. In particular, EPHB2 was associated with poor breast cancer survival in a number of materials, and depending on cell location, EPHB2 protein expression also has prognostic significance.
Husa, Anna-Maria, et al. "EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer." Oncotarget 7.16 (2016): 21362.
Pubmed:
26870995
DOI:
10.18632/oncotarget.7246